Microvesicle histone h2ax as a biomarker for genotoxic stress

ABSTRACT

The invention described herein relates to methods of monitoring genotoxic stress in a test subject, specifically by detecting the expression level of microvesicle-associated H2AX from a biological sample.

CROSS-REFERENCE TO RELATED APPLICATION(S)

This application claims the benefit of U.S. Provisional Application No.61/785,552 filed Mar. 14, 2013, which is incorporated herein byreference in its entirety.

FIELD

The present disclosure relates to methods of monitoring genotoxic stressin a test subject, specifically by detecting the expression level ofmicrovesicle-associated H2AX from a biological sample.

BACKGROUND

Agents that damage DNA or interfere with replication can be present inthe environment, accidentally released, and/or intentionallyadministered. Exposure to these agents causes genotoxic stress in a widevariety of organisms. To assess the extent of damage/interference andwhether such effects outweigh potential benefits arising from use of theagent, it is necessary to monitor, detect and/or measure genotoxicstress.

Agents that damage DNA or interfere with replication are commonlyadministered as a part of cancer treatment. Cancer is a leading cause ofdeath worldwide. In 2004, it accounted for 7.4 million deaths (around13% of all deaths). Deaths from cancer are expected to continue to rise,with a predicted 12 million deaths in 2030 (WHO, February 2009). Varioustreatments are available for cancer patients, such as chemotherapy,radiation, surgery, and drug therapy. Effective monitoring of cancerprogression and treatment efficacy are critical to reducing theworldwide cancer burden, yet the development of robust and non-invasivemethods and tools for monitoring disease progression and treatmentefficacy remain major challenges in the field. Furthermore, a largeproportion of patients with cancer, such as breast cancer and prostatecancer, are over-treated, resulting in wasted time and expense andunnecessary exposure of patients to unpleasant treatments and dangerousside effects (Hartmann et al., Lancet 2010, 11: 383-390). Effective,non-invasive monitoring of a patient's response to a treatment wouldgreatly improve the efficiency of cancer management.

For many types of cancers, the current means of monitoring the efficacyof a given treatment of cancer in the patient involve histopathology ofa tissue sample or imaging studies, which involve painful and invasivebiopsies or risks associated with imaging such as exposure to radiation.These processes are often uncomfortable, expensive and inaccurate due tosubjective interpretation by different technicians and clinicians. Thus,a need remains for sensitive, non-invasive, and rapid means formonitoring the efficacy of a given treatment for cancer patients.

Expression levels of specific proteins have been shown to have potentialas an informative and reliable tool for making diagnoses, monitoring theefficacy of cancer treatment, and predicting prognoses. However, veryfew protein diagnostic markers have been developed to date (Anderson andAnderson, Mol Cell Proteomics 2002, 1.11: 845-867; Sanchez-Carbayo,Tumor Biol 2010, 31: 103-112).

An unmet need exists in the field of cancer biology for better methodsof monitoring the efficacy of treatment in cancer patients. Ideallythese methods would be less invasive and less painful and discomfortingthan are currently available monitoring techniques.

BRIEF SUMMARY OF PREFERRED EMBODIMENTS

The invention described herein meets the needs described above byproviding methods of monitoring genotoxic stress in a test subject,specifically by detecting the expression level ofmicrovesicle-associated H2AX in a biological sample. The H2AX to bedetected may either be unphosphorylated or phosphorylated. In certainembodiments the phosphorylated H2AX is γH2AX.

In some embodiments, the genotoxic stress is due to environmentalcontamination or radiation exposure. In other embodiments, the genotoxicstress is due to cancer treatment, such as administration of ananti-cancer agent or exposure to radiation. Thus, methods describedherein include methods of monitoring genotoxic stress due to cancertreatment in a test subject by detecting the expression level ofmicrovesicle-associated H2AX in a test subject, and monitoring thecancer treatment in the subject based on the expression level of themicrovesicle-associated H2AX. In some embodiments, detecting theexpression level of microvesicle-associated H2AX in a biological samplefrom the test subject occurs at a plurality of time points followingadministration of the cancer treatment.

In certain embodiments of the above aspect, the cancer treatmentincludes administration of an anti-cancer agent such as a platinumanalogue, a tetrazine, an anti-metabolite, a plant alkaloid orterpenoid, a cytotoxic antibiotic, a DNA alkylating agent (e.g.,temozolomide), or a type I topoisomerase inhibitor (e.g.,indenoisoquinoline).

In certain embodiments, monitoring the genotoxic stress involvescomparing the expression level of H2AX in the biological sample from thetest subject with the expression level of H2AX in a biological samplefrom a control subject that is not given the cancer treatment.

In certain embodiments, a higher level of expression of H2AX in thebiological sample from the test subject compared to the level ofexpression of H2AX in the biological sample from the control subject mayindicate that the cancer treatment is inhibiting replication of DNA incancer cells in the test subject.

In some embodiments, monitoring the genotoxic stress involves evaluatingthe efficacy of the cancer treatment. In preferred embodiments,evaluating the efficacy of the cancer treatment in the test subjectinvolves comparing the expression level of H2AX in the biological samplefrom the test subject with the expression level of H2AX in biologicalsamples from a plurality of control subjects.

In certain embodiments, the plurality of control subjects have the sametype of cancer as the test subject and are administered the same cancertreatment as the test subject. In other preferred embodiments, thecancer treatment has a different level of treatment efficacy in each ofthe plurality of control subjects.

In some embodiments, a step is included for deriving a score from thecomparison of the expression level of H2AX in the biological sample fromthe test subject with the expression level of H2AX in the biologicalsamples from the plurality of control subjects, where the scoreindicates a level of similarity between the expression level of H2AX inthe biological sample from the test subject and the expression level ofH2AX in the biological samples from the plurality of control subjects.In preferred embodiments, determining the level of efficacy of thecancer treatment in the test subject is based on the above mentionedscore. In additional preferred embodiments, the score used indetermining the efficacy of the cancer treatment in the test subject isa correlation coefficient.

In preferred embodiments, the cancer in the above embodiments is a solidtumor. In other embodiments, the cancer is pancreatic, ovarian,adenocarcinoma, prostate, breast, brain, head, neck, cervical, orlymphoma cancers. The brain cancer can be glioblastoma multiforme (WHOgrade III and IV) or lower grade malignancies including, for example,anaplastic astrocytoma, oligoastrocytoma, oligodendrogliomas;ependymoma, medulloblastoma, meningioma, pineal tumors, or pituitarytumors.

In certain embodiments, the biological sample in the above embodimentsis plasma, serum, cerebrospinal fluid, urine, tears, milk, lymph fluid,synovial fluid, bronchoalveolar lavage, amniotic fluid, saliva, ocularfluid, ascites, and respiratory droplets.

In certain embodiments, detecting the expression level of H2AX involvesdetecting binding of H2AX to an H2AX-specific antibody. In preferredembodiments, the antibody is covalently bound to a bead. In yetadditional preferred embodiments, detecting binding of H2AX to anH2AX-specific antibody involves detecting fluorescence. In otherembodiments, detecting the expression level of microvesicle-associatedH2AX involves the use of ELISA, flow cytometry, or liquidchromatography-mass spectrometry.

In certain embodiments, isolating microvesicles from the biologicalsample prior to detecting the expression level of H2AX involvescontacting the biological sample with a cancer-derivedmicrovesicle-specific reagent where the biological sample includesmicrovesicles and the reagent binds to the microvesicles, contacting themicrovesicles with a tissue-specific reagent, and isolating themicrovesicles derived from the tissue.

Certain aspects of the present disclosure relate to methods ofmonitoring genotoxic stress in a test subject by detecting theexpression level of microvesicle-associated histone proteins in abiological sample from the test subject, and monitoring genotoxic stressin the subject based on the expression level of themicrovesicle-associated histone protein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates a Western gel blot analysis of U87 brain tumorcell-shed microvesicle-derived total protein content from variousmicrovesicle samples as a function of time or exposure tochemotherapeutic agent temozolomide (TMZ).

FIG. 2A illustrates a Western blot analysis of γH2AX protein present inthe various microvesicle samples. FIG. 2B illustrates a Western blotanalysis of H2AX protein present in the various microvesicle samples.

FIG. 3A illustrates a Western blot analysis of γH2AX protein present invarious subcellular compartment samples from cells of the U87 tumorcolony. FIG. 3B illustrates a Western blot analysis of H2AX proteinpresent in various subcellular compartment samples.

FIG. 3C illustrates a legend of the subcellular compartments analyzed inthe blot and their respective labels.

FIG. 4 illustrates a Western blot analysis of H2AX, γH2AX, andpan-Histone proteins present in microvesicle preparations from U87,Hela, and HEK293T cells under various conditions.

DETAILED DESCRIPTION

The present disclosure relates to methods of monitoring genotoxic stressin a test subject, specifically by detecting the expression level ofmicrovesicle-associated H2AX, either unphosphorylated or in itsphosphorylated form (e.g., γH2AX), in a biological sample.

Histones are proteins which package DNA into nucleosomes, the repeatingunits that make up chromatin. Histone H2A is one of the five types ofhistone proteins. There are several non-allelic variants of histone H2A.The variant histone H2AX has a C terminal tail that is used for DNArepair.

Without wishing to be bound by theory, it is believed that H2AX andγH2AX are markers for genotoxic stress due to the role that histonesplay in packaging DNA into nucleosomes. Furthermore, phosphorylation ofhistone H2AX to γH2AX (ser 139) is a robust early indicator of DNAdamage such as double stranded breaks (DSBs).

Thus, the present disclosure includes the discovery of a non-invasivemethod for monitoring genotoxic stress in a test subject by detectingthe expression level of H2AX associated with microvesicles.

Genotoxic stress in a test subject can be induced by a variety ofcircumstances, for example, accidental exposure of subjects togenotoxins (e.g., environmental contamination) or radiation, hostileexposure to genotoxins or radiation, and cancer treatment designed toslow or stop the growth of rapidly dividing cancer cells. It should beunderstood by one of skill in the art that the embodiments describedherein with respect to methods for monitoring genotoxic stress due tocancer treatment are also embodiments of methods for monitoringgenotoxic stress induced by other circumstances.

Definitions

In order to facilitate an understanding of the disclosure, selectedterms used in the application will be discussed below.

“γH2AX” as used herein refers to a gamma-phosphorylated H2AX protein(i.e., phosphorylated on Serine 137). H2AX is a variant of the histoneprotein H2A.

When the term “H2AX” is used herein, it refers to all derivatives ofH2AX, including both the unphosphorylated and phosphorylated forms ofthe protein. The phosphorylated residue of the derivative may be Serine137 or another residue.

“Monitoring” as used herein refers to the act of observing. Monitoring atreatment may include observing a change in the expression level of aprotein in an individual receiving that treatment over time.

“Microvesicle” as used herein refers to any small vesicle released fromany cell type. Microvesicles include, for example, endosome-derivedexosomes, plasma membrane-derived shedding vesicles, apoptotic bodies,prostasomes, P2 and P4 particles, and outer membrane vesicles (OMVs).Shedding vesicles may be referred to as ectosomes, microparticles,shedding bodies, exovesicles, or secretory vesicles. Protasomes may bereferred to as aposomes or seminosomes. P2 and P4 particles may bereferred to as prominosomes.

A “microvesicle-associated protein” as used herein refers to any proteinthat has been contained within or located on the surface of amicrovesicle. “Microvesicle-associated protein” can refer to such aprotein while the protein is still associated with a microvesicle orafter the protein is no longer associated with a microvesicle. Inpreferred embodiments, the microvesicle-associated protein is γH2AX.

Monitoring Genotoxic Stress Due to Cancer Treatment MonitoringExpression Levels of Microvesicle-Associated H2AX in Test and ControlSubjects

Described herein are methods of monitoring, detecting or measuringgenotoxic stress due to cancer treatment, specifically by detecting theexpression level of microvesicle-associated H2AX in a biological samplefrom a test subject.

The cancer treatment may be any treatment which is used to slow or stopthe progression of the cancer. Such treatments may work via a widevariety of mechanisms ranging from alkylating DNA to interfering withother aspects of the DNA replication process. Exemplary methods includetreatment with anti-cancer agents and/or exposure to radiation.

Anti-cancer agents include classical DNA alkylating agents such astemozolomide; nitrogen mustard; cyclophosphamide; mechlorethamine ormustine (HN2) (trade name Mustardgen); uramustine or uracil mustard;melphalan; chlorambucil; ifosfamide; nitrosoureas such as carmustine,lomustine and streptozocin; alkyl sulfonates such as busulfan; andThiotepa. Certain alkylating agents are described as “non-classical”.Examples of non-classical alkylating agents include procarbazine andaltretamine.

Other anti-cancer agents are considered to be alkylating-like, sincethey do not have an alkylating group, but nevertheless damage DNA.Alkylating-like drugs include the platinum-based chemotherapeutic drugs(termed platinum analogues) such as cisplatin, carboplatin, nedaplatin,oxaliplatin, satraplatin, and triplatin tetranitrate,

In some embodiments, the anti-cancer agent is a tetrazine, e.g.,dacarbazine, mitozolomide, or temozolomide.

Other exemplary anti-cancer agents include anti-metabolites which mimicpurines (e.g., azathioprine, mercaptopurine) or pyrimidines and becomeincorporated into the DNA.

Additional exemplary anti-cancer agents are the plant alkaloids andterpenoids, which block cell division by preventing microtubulefunction. The main examples of such anti-cancer agents are Vincaalkaloids and taxanes. The Vinca alkaloids include, without limitation,vincristine, vinblastine, vinorelbine, and vindesine. The taxanesinclude, without limitation, paclitaxel, originally known as Taxol anddocetaxel. a semi-synthetic analogue of paclitaxel.

Anti-cancer agents also include topoisomerase inhibitors. Type Itopoisomerase inhibitors include the camptothecins, irinotecan andtopotecan. Type II inhibitors include amsacrine, etoposide, etoposidephosphate, and teniposide. These are semisynthetic derivatives ofepipodophyllotoxins.

Anti-cancer agents also include cytotoxic antibiotics, for example,actinomycin, anthracyclines (e.g., doxorubicin, daunorubicin,vahrubicin, idarubicin, epirubicin), bleomycin, plicamycin, andmitomycin.

In certain embodiments, the anti-cancer agents are DNA alkylatingagents, such as temozolomide, or topoisomerase inhibitors, such asindenoisoquinoline,

The indenoisoquinoline may include, without limitation, National CancerInstitute lead compounds NSC 706744, NSC 725776 (Indimitecan), NSC724998 (Indotecan), as well as6-Ethyl-5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline,5,6-Dihydro-5,11-diketo-6-propyl-11H-indeno[1,2-c]isoquinoline,6-Cyclopropyl-5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline,5,6-Dihydro-5,11-diketo-6(methoxycarbonylmethyl)-11H-indeno[1,2-c]isoquinoline,5,6-Dihydro-6-(4-hydroxy-1-butyl)-5,11-diketollH-indeno[1,2-c]isoquinoline,5,6-Dihydroxy-6-(5-hydroxy-1-pentyl)-5,11-diketollH-indeno[1,2-c]isoquinoline,cis-4-Carboxy-3,4-dihydro-N-methyl-3-(3′,4′methylenedioxyphenyl)-1(2H)isoquinolone,5,6-Dihydro-5,11-diketo-6-methyl-8,9methylenedioxy-11H-indeno[1,2-c]isoquinoline,cis-N-(1-Butyl)-4-carboxy-3,4-dihydro-3-(3′,4′methylenedioxyphenyl)-1(2H)-isoquinolone,6-(1-Butyl)-5,6-dihydro-5,11-diketo-8,9methylenedioxy-11H-indeno[1,2-c]isoquinoline,cis-N-Ally-4-carboxy-3,4-dihydro-6,7-dimethoxy-3(3′,4′-methylenedioxyphenyl)-1(2H)isoquinolone,6-Allyl-2,3-dimethoxy-5,6-dihydro-5,11-oxo-8,9(methylenedioxy)-11H-indeno[1,2c]isoquinoline,cis-N-(1-Butyl)-4-carboxy-3,4-dihydro-6,7dimethoxy-3-(3′,4′methylenedioxyphenyl)-1(2H)isoquinolone,6-(1-Butyl)-5,6-dihydro-5,11-diketo-2,3-dimethoxy8,9-methylenedioxy11H-indeno[1,2-c]isoquinoline,cis-N-Benzyl-4-carboxy-3,4-dihydro-6,7-dimethoxy3-(3′,4′-methylenedioxyphenyl)-1(2H)isoquinolone,6-Benzyl-5,6-dihydro-5,11-diketo2,3-dimethoxy-8,9-methylenedioxy-11H-indeno[1,2-c]isoquinoline,cis-N-(p-Anisyl)-4-carboxy-3,4-dihydro-6,7dimethoxy-3-(3′,4′-methylene-dioxyphenyl)-1(2H)isoquinolone,6-(p-Anisyl)-2,3-dimethoxy-5,6-dihydro-5,11diketo-8,9-methylenedioxy-11H-indeno[1,2-c]isoquinoline,cis-3-(3′,4′-Dibenzyloxyphenyl)-4-carboxy-3,4dihydro-N-methyl-1-2H-isoquinolone,8,9-Dibenzyloxy-5,6-dihydro-5,11-diketo-6-methyl11H-indeno[1,2-c]isoquinoline,cis-3-(3′,4′-Dibenzyloxyphenyl)-4-carboxy-3,4dihydro-N-methyl-6,7-dimethoxy-1-(2H)-isoquinolone,8,9-Dibenzyloxy-5,6-dihydro-5,11-diketo-6-methyl2,3-dimethoxy-11H-indeno[1,2-c]isoquinoline,cis-4-Carboxy-3,4-dihydro-N-methyl-6,7dimethoxy-3-(3′,4′,5′-trimethoxyphenyl)-1(2H)isoquinolone,5,6-Dihydro-5,11-diketo-6methyl-2,3,8,9,10pentamethoxy-11H-indeno[1,c]isoquinoline,cis-4-Carboxy-3,4-dihydro-N-methyl-3(3′,4′,5′trimethoxyphenyl)-1(2H)isoquinolone,5,6-Dihydro-5,11-diketo-6-methyl-8,9,1Otrimethoxy-11H-indeno[1,2-c]isoquinoline,cis-4-Carboxy-N-ethyl-3-(3′,4′-methylenedioxyphenyl)-6,7-dimethoxy3,4-dihydro-1(2H)isoquinolone,6-Ethyl-5,6-dihydro-5,11-diketo-2,3-dimethoxy-8,9methylenedioxy-11H-indeno[1,2-c]isoquinoline,5,6-Dihydro-5,11-diketo-6-(4-hydroxybut-1-yl)-2,3dimethoxy-8,9-methylenedioxy-(11H)indeno[1,2-c]isoquinoline,5,6-Dihydro-6-(4-hydroxypent-1-yl)-5,11-diketo-2,3-dimethoxy-8,9-methylenedioxy-11Hindenoisoquinoline,cis-5,6,12,13-Tetrahydro-2,3-dimethoxy-6-methyl-5,11-dioxo-8,9(methylenedioxy)-(11H)indeno[1,2-c]isoquinoline,cis-6-Ethyl-5,6,12,13-tetrahydro-2,3-dimethoxy-5,11-dioxo-8,9-(methylene-dioxy)-11H-indeno[1,2-c]isoquinoline,cis-6-Allyl-5,6,12,13-tetrahydro-2,3-dimethoxy-5,11-dioxo-8,9-(methylenedioxy)-(11H)indeno[1,2-c]isoquinoline,5,6-Dihydro-5,11-diketo-2,3,8-trimethoxy-6-methyl9[(methylsulfonyl)oxy]-(11H)indeno[1,2-c]isoquinoline,6-Ethyl-5,6,12a,13a-tetrahydro-11-hydroxy-2,3dimethoxy-8,9-(methylenedioxy)-5-oxo-11H-indeno[1,2-c]isoquinoline,6-Ethyl-5,6,12a,13a-tetrahydro-11^(˜)-hydroxy-2,3dimethoxy-8,9-(methylenedioxy)-11H-indeno[1,2-c]isoquinoline,6-(3-Carboxy-1-propyl)-5,6-dihydro-5,11-diketol1H-indeno[1,2-c]isoquinoline,or6-Ethyl-2,3-dimethoxy-8,9-(methylenedioxy)-11Hindeno[1,2-c]isoquinoliniumChloride.

In certain embodiments, detecting the expression level ofmicrovesicle-associated γH2AX in a biological sample from the testsubject occurs at a plurality of time points following administration ofthe cancer treatment.

In certain embodiments, as disclosed herein, detecting the expressionlevel of microvesicle-associated H2AX in a biological sample from thetest subject following cancer treatment occurs at least after one day,at least after 3 days, at least after 4 days, at least after 5 days, atleast after 6 days, at least after 7 days, at least after 8 days, atleast after 10 days, at least after 12 days, at least after 14 days, atleast after 16 days, at least after 18 days, at least after 20 days, atleast after 21 days, at least after 25 days, at least after 30 days, atleast after 2 months, at least after 4 months, at least after 6 months,at least after 8 months, at least or after 12 months.

In preferred embodiments, monitoring the cancer treatment involvescomparing the expression level of H2AX in the biological sample from thetest subject with the expression level of H2AX in a biological samplefrom a control subject that is not given the cancer treatment.

In certain embodiments, a higher level of expression of H2AX in thebiological sample from the test subject compared to the level ofexpression of H2AX in the biological sample from the control subjectindicates that the cancer treatment is inducing genotoxic stress in thetest subject. Typically, an expression level is said to be increased ordecreased relative to a second expression level if the differencebetween the two expression levels is statistically significant. Thedifference between two levels is considered to be statisticallysignificant if it was unlikely to have occurred by chance. Statisticalsignificance may be measured by any means known in the art, such as, forexample, Fisherian statistical hypothesis testing or the Neyman-Pearsonlemma.

In certain embodiments, monitoring the cancer treatment includesevaluating the efficacy of the cancer treatment in the test subject.Evaluating the efficacy may include methods of comparing the expressionlevel of H2AX in the biological sample from the test subject with theexpression level of H2AX in biological samples from a plurality ofcontrol subjects. Evaluating the efficacy may further include methodsfor assigning a score to the test subject based on expression levels ofH2AX in test subjects compared to control subjects.

Typically, each of the plurality of control subjects has the same typeof cancer as the test subject and is administered the same cancertreatment as the test subject.

In certain embodiments, the cancer treatment has a different level oftreatment efficacy in each of the plurality of control subjects.

In certain embodiments, a step is included for deriving a score from thecomparison of the expression level of H2AX in the biological sample fromthe test subject with the expression level of H2AX in the biologicalsamples from the plurality of control subjects, where the scoreindicates a level of similarity between the expression level of H2AX inthe biological sample from the test subject and the expression level ofH2AX in the biological samples from the plurality of control subjects.In preferred embodiments, determining the level of efficacy of thecancer treatment in the test subject is based on the above mentionedscore.

The score may be derived by any methods known to one of skill in theart. In certain embodiments, the score may simply be a measure of thedifference in expression levels. In preferred embodiments, the score isa correlation coefficient. A correlation coefficient describes thesimilarity between two expression patterns. Expression levels may beconsidered similar if the correlation coefficient is greater than orequal to 0.5. In preferred embodiments, for expression levels to beconsidered significantly similar, the correlation coefficient should begreater than 0.6, 0.7, 0.8, 0.9, or 0.95. In other embodiments, thescore is generated by other statistical methods which produce a measureof mutual information to describe the similarity between two expressionpatterns. Expression levels may be considered similar if the normalizedmutual information value is greater than or equal to 0.7. In preferredembodiments, for the expression levels to be considered significantlysimilar, the normalized mutual information value should be greater than0.8, 0.9, or 0.95.

If the score indicates a significant level of similarity between theexpression level of microvesicle-associated H2AX in the biologicalsample from the test subject and the expression level ofmicrovesicle-associated H2AX in biological samples from the plurality ofcontrol subjects, then the test subject can be said to have or to belikely to have the same efficacy of cancer treatment as that of theplurality of control subjects. For example, if the score indicates asignificant level of similarity between the expression level of H2AX inthe biological sample from the test subject and the expression level ofH2AX in biological samples from the plurality of control subjects whoare not given the cancer treatment, then the cancer treatment can besaid to be or likely to be efficacious.

Types of Cancer

The described methods may be applied to treatment of any type of cancerincluding, without limitation, adult acute lymphoblastic leukemia,childhood acute lymphoblastic leukemia, adult acute myeloid leukemia,childhood acute myeloid leukemia, adrenocortical carcinoma, childhoodadrenocortical carcinoma, aids-related cancers, aids-related lymphoma,anal cancer, appendix cancer, basal cell carcinoma, extrahepatic bileduct cancer, bladder cancer, childhood bladder cancer, bone cancer,osteosarcoma and malignant fibrous histiocytoma, childhood brain stemglioma, adult brain tumor, childhood central nervous system atypicalteratoid/rhabdoid tumor, childhood central nervous system embryonaltumors, childhood astrocytomas, childhood pineal parenchymal tumors ofintermediate differentiation, childhood supratentorial primitiveneuroectodermal tumors and pineoblastoma, childhood brain and spinalcord tumors, breast cancer, childhood breast cancer, male breast cancer,childhood bronchial tumors, burkitt lymphoma, childhood carcinoid tumor,primary central nervous system lymphoma, cervical cancer, childhoodcervical cancer, childhood chordoma, chronic lymphocytic leukemia,chronic myelogenous leukemia, chronic myeloproliferative disorders,colon cancer, childhood colorectal cancer, childhood craniopharyngioma,childhood central nervous system embryonal tumors, endometrial cancer,childhood ependymoblastoma, childhood ependymoma, esophageal cancer,childhood esophageal cancer, Ewing sarcoma family of tumors, childhoodextracranial germ cell tumor, extragonadal germ cell tumor, gallbladdercancer, gastric (stomach) cancer, childhood gastric (stomach) cancer,gastrointestinal carcinoid tumor, gastrointestinal stromal tumor (gist),childhood gastrointestinal stromal cell tumor, extragonadal germ celltumor, ovarian germ cell tumor, gestational trophoblastic tumor, adultglioma, hairy cell leukemia, head and neck cancer, adult (primary)hepatocellular (liver) cancer, childhood (primary) hepatocellular(liver) cancer, adult Hodgkin lymphoma, childhood Hodgkin lymphoma,hypopharyngeal cancer, intraocular melanoma, islet cell tumors(endocrine pancreas), Kaposi sarcoma, kidney (renal cell) cancer,childhood kidney cancer, Langerhans cell histiocytosis, laryngealcancer, childhood laryngeal cancer, chronic lymphocytic leukemia,chronic myelogenous leukemia, hairy cell leukemia, lip and oral cavitycancer, adult (primary) liver cancer, childhood (primary) liver cancer,non-small cell lung cancer, small cell lung cancer, adult non-Hodgkinlymphoma, childhood non-Hodgkin lymphoma, primary central nervous systemlymphoma, Waldenström macroglobulinemia, malignant fibrous histiocytomaof bone and osteosarcoma, childhood medulloblastoma, childhoodmedulloepithelioma, melanoma, Merkel cell carcinoma, adult malignantmesothelioma, childhood mesothelioma, metastatic squamous neck cancerwith occult primary, mouth cancer, childhood multiple endocrineneoplasia syndrome, multiple myeloma/plasma cell neoplasm, mycosisfungoides, myelodysplastic syndromes, myelodysplastic/myeloproliferativeneoplasms, chronic myelogenous leukemia, multiple myeloma, chronicmyeloproliferative disorders, nasal cavity and paranasal sinus cancer,nasopharyngeal cancer, childhood nasopharyngeal cancer, neuroblastoma,childhood oral cancer, oropharyngeal cancer, childhood ovarian cancer,ovarian epithelial cancer, ovarian germ cell tumor, ovarian lowmalignant potential tumor, pancreatic cancer, childhood pancreaticcancer, childhood papillomatosis, parathyroid cancer, penile cancer,pharyngeal cancer, pituitary tumor, plasma cell neoplasm/multiplemyeloma, pleuropulmonary blastoma, prostate cancer, rectal cancer,respiratory tract carcinoma involving the nut gene on chromosome 15,retinoblastoma, childhood rhabdomyosarcoma, salivary gland cancer,childhood salivary gland cancer, adult soft tissue sarcoma, childhoodsoft tissue sarcoma, uterine sarcoma, Sézary syndrome, skin cancer(nonmelanoma), childhood skin cancer, skin cancer (melanoma), Merkelcell skin carcinoma, small intestine cancer, adult soft tissue sarcoma,childhood soft tissue sarcoma, squamous cell carcinoma, cutaneous t-celllymphoma, testicular cancer, throat cancer, thymoma and thymiccarcinoma, childhood thymoma and thymic carcinoma, thyroid cancer,childhood thyroid cancer, gestational trophoblastic tumor, transitionalcell cancer of ureter and renal pelvis, urethral cancer, endometrialuterine cancer, uterine sarcoma, vaginal cancer, childhood vaginalcancer, vulvar cancer, or Wilms' tumor. The brain cancer can beglioblastoma multiforme (WHO grade III and IV) or lower grademalignancies including, for example, anaplastic astrocytoma,oligoastrocytoma, oligodendrogliomas; ependymoma, medulloblastoma,meningioma, pineal tumors, or pituitary tumors.

In some embodiments, treatment is for cancer that is a solid tumor. Inother embodiments, the treatment is for a blood cancer such as leukemia,lymphoma, and myeloma. In certain embodiments, the cancer is selectedfrom pancreatic, ovarian, adenocarcinoma, brain, prostate, breast, head,neck, or lymphoma cancers. In certain embodiments the cancer is aglioma, such as glioblastoma multiforme.

Detecting Expression Levels of Protein Biomarkers

Methods of the present disclosure include a step of detecting theexpression level of microvesicle-associated H2AX, either when associatedwith the microvesicle or subsequent to dissociation from themicrovesicle.

Protein level of H2AX is detected. In preferred embodiments, detectingthe expression level of H2AX involves detecting binding of H2AX to anH2AX-specific antibody, e.g., ELISA. In additional preferredembodiments, the antibody is covalently bound to a bead. In yetadditional preferred embodiments, detecting binding of H2AX to anH2AX-specific antibody involves detecting fluorescence. In otherembodiments, the level of H2AX is measured directly, using for example,flow cytometry or a liquid chromatography-mass spectrometry.

In other embodiments, the method involves isolating cancer-derivedmicrovesicles from the biological sample prior to detecting theexpression level of H2AX. In preferred embodiments, isolatingmicrovesicles from the biological sample prior to detecting theexpression level of H2AX involves contacting the biological sample witha cancer-derived microvesicle-specific reagent where the biologicalsample includes microvesicles and the reagent binds to themicrovesicles, contacting the microvesicles with a tissue-specificreagent, and isolating the microvesicles derived from the tissue.

The expression level of H2AX may include a relative or absolute amountof a protein in a sample, or it may simply refer to the presence orabsence of a protein in a sample. The expression level of themicrovesicle-associated H2AX may be detected by any methods known to oneof skill in the art (see, for example: Coligan et al, Unit 9, CurrentProtocols in Immunology, Wiley Interscience, 1994), which include,without limitation: immunohistochemistry (Microscopy,Immunohistochemistry and Antigen Retrieval Methods for Light andElectron Microscopy, M. A. Hayat (Author), Kluwer Academic Publishers,2002; Brown C.: “Antigen retrieval methods for immunohistochemistry,”Toxicol Pathol 1998; 26(6): 830-1), ELISA (Onorato et al.,“Immunohistochemical and ELISA assays for biomarkers of oxidative stressin aging and disease,” Ann NY Acad Sci 1998 20; 854: 277-90), Westernblotting (Laemmeli U K: “Cleavage of structural proteins during theassembly of the head of a bacteriophage T4,” Nature 1970; 227: 680-685;Egger & Bienz, “Protein (western) blotting”, Mol Biotechnol 1994; 1(3):289-305), and antibody microarray hybridization (Huang, “Detection ofmultiple proteins in an antibody-based protein microarray system,”Immunol Methods 2001 1; 255 (1-2): 1-13).

Typically, one of two approaches may be used in preparation fordetecting the expression levels of the microvesicle-associated H2AX. Inthe first approach, the protein is dissociated from microvesicles. Forexample, the microvesicles are lysed, and the proteins in themicrovesicles are extracted, precipitated, and reconstituted foranalysis. In the second approach, the microvesicles are kept intact sothat the protein remains associated, and the microvesicles are attachedto a column, resin, or bead. The reconstituted protein or themicrovesicles attached to a column, resin, or bead are used in thedetection step. For example, the reconstituted protein or themicrovesicles attached to a column, resin, or bead are contacted with anantibody specific to the H2AX biomarker.

In preferred embodiments, detecting the expression level includesdetecting binding of H2AX to an antibody specific to this protein.Antibodies may be monoclonal or polyclonal, and they may be obtainedfrom a commercial source or generated for use in the methods describedherein. Methods for producing and evaluating antibodies are well knownin the art, see, e.g., Coligan, (1997) Current Protocols in Immunology,John Wiley & Sons, Inc; and Harlow and Lane (1989) Antibodies: ALaboratory Manual, Cold Spring Harbor Press, NY (“Harlow and Lane”).

The antibody may be covalently bound to a bead or fixed on a solidsurface, such as glass, plastic, or silicon chip. Typically, thebiological sample is contacted with an antibody specific to H2AX. AnyH2AX protein present in the sample will bind to the H2AX antibody. Themixture is washed, and the antibody-protein biomarker complexes can bedetected. In preferred embodiments, H2AX is detected after the proteinbinds to an anti-H2AX antibody that is bound to a bead.

This detection can be achieved by contacting the washed antibody-proteinbiomarker complexes with a detection reagent. This detection reagent maybe, for example, a secondary antibody which is labeled with a detectablelabel. Exemplary detectable labels include magnetic beads (e.g.,DYNABEADS™), fluorescent dyes, radiolabels, enzymes (e.g., horseradishperoxide, alkaline phosphatase, and others commonly used in ELISA), andcolorimetric labels such as colloidal gold, colored glass, or plasticbeads. In preferred embodiments, H2AX is detected after the proteinbinds to an anti-H2AX antibody and includes detection of fluorescence.

Methods for measuring the amount of, or presence of, antibody-markercomplexes include, for example, detection of fluorescence, luminescence,chemiluminescence, absorbance, reflectance, transmittance,birefringence, or refractive index (e.g., surface plasmon resonance,ellipsometry, a resonant mirror method, a grating coupler waveguidemethod, or interferometry). Optical methods include microscopy (bothconfocal and non-confocal), imaging methods, and non-imaging methods.Electrochemical methods include voltametry and amperometry methods.Radio frequency methods include multipolar resonance spectroscopy.Methods for performing these assays are readily known in the art. Usefulassays include, for example, an enzyme immune assay (EIA) such asenzyme-linked immunosorbent assay (ELISA), a radioimmune assay (RIA), aWestern blot assay, or a slot blot assay. These methods are alsodescribed in, e.g., Methods in Cell Biology: Antibodies in Cell Biology,volume 37 (Asai, ed. 1993); Basic and Clinical Immunology (Stites &Terr, eds., 7th ed. 1991); and Harlow & Lane, supra. In preferredembodiments, H2AX is detected after the protein binds to an anti-H2AXantibody and includes detection of fluorescence.

Throughout the assays, incubation and/or washing steps may be requiredafter each combination of reagents. Incubation steps can vary from about5 seconds to several hours, preferably from about 5 minutes to about 24hours. However, the incubation time will depend upon the assay format,marker, volume of solution, concentrations, and the like. Usually theassays will be carried out at ambient temperature, although they can beconducted over a range of temperatures, such as 10° C. to 40° C.

Immunoassays can be used to determine the presence or absence of amarker in a sample as well as the quantity of a marker in a sample. Theamount of an H2AX/anti-H2AX complex can be determined by comparing to astandard. A standard can be, e.g., a known compound or another proteinknown to be present in a sample. As noted above, the test amount of H2AXneed not be measured in absolute units, as long as the unit ofmeasurement can be compared to a control.

Biological Samples

The methods include detecting the expression level ofmicrovesicle-associated H2AX in a biological sample from the testsubject. The biological sample may be any sample from the body of thetest subject that contains microvesicles. In preferred embodiments, thebiological sample is a bodily fluid. As used herein, a “bodily fluid”refers to a sample of fluid isolated from anywhere in the body of thetest subject, preferably a peripheral location, including but notlimited to, for example, blood, plasma, serum, urine, sputum, spinalfluid, pleural fluid, nipple aspirates, lymph fluid, respiratorydroplets, intestinal, and genitourinary tracts, tears, saliva, breastmilk, fluid from the lymphatic system, semen, cerebrospinal fluid,intra-organ system fluid, ascitic fluid, tumor cyst fluid, synovialfluid, amniotic fluid, ocular fluid, ascites, bronchoalveolar lavage,and combinations thereof. In particularly preferred embodiments, thebiological sample is blood. If the sample is blood, is it preferablycentrifuged to remove cellular material and debris such that a plasmafraction is generated.

In especially preferred embodiments, the biological sample includes, butis not limited to, plasma, serum, cerebrospinal fluid, urine, tears,milk, lymph fluid, synovial fluid, bronchoalveolar lavage, amnioticfluid, saliva, ocular fluid, ascites, and respiratory droplets.

The H2AX detected in the methods are associated with microvesiclespresent in the biological sample. The microvesicles may be derived fromendosomes (exosomes) or from the plasma membrane (shedding vesicles).The microvesicles may also be, for example, apoptotic bodies,prostasomes, P2 and P4 particles, or outer membrane vesicles (OMVs). The1H2AX associated with the microvesicles may be membrane proteins orcytosolic proteins.

Isolation of Microvesicles

The methods may include a step of isolating microvesicles from thebiological sample prior to detecting the expression level of H2AX.Various different populations of microvesicles may be isolated. Forexample, when the methods relate to detection of the expression level ofH2AX expressed by all tissues, the entire population of microvesicles isisolated. When the methods relate to detection of the expression levelof expressed by multiple tissues, a specific sub-population ofmicrovesicles derived from these tissues is isolated. When the methodsrelate to detection of the expression level of protein biomarkersexpressed by a single tissue, microvesicles derived from that specifictissue are isolated. In preferred embodiments, microvesicles fromvarious tissues are isolated by contacting microvesicles with atissue-specific reagent.

The entire population of microvesicles may be isolated according to anymethods known to one of skill in the art (see, for example, Cocucci etal., Traffic 8, 2007: 742-757; Simpson et al., Proteomics 8, 2008:4083-4099). In certain embodiments, isolating microvesicles involvescentrifugation. For example, serial centrifugation may be used to removecells and debris, and microvesicles may be pelleted using sedimentationat 60-100,000×g for 1 hour or longer. Additional methods of differentialcentrifugation are described in Raposo et al., J Exp Med 183, 1996:1161-72. In other embodiments, techniques such as filtration, sucrosedensity gradients, organelle electrophoresis, anion exchange and/or gelpermeation chromatography, magnetic activated cell sorting (MACS),nanomembrane ultrafiltration concentration, and microchips withmicrofluidic technology may be used to isolate microvesicles. Forexample, large cell debris may be removed by filtration with a 0.22 m ora 0.1 m filter. Microvesicles may be isolated by passing the biologicalsample through a filter having an average pore diameter of between 0.01m and about 0.15 μm. Linear sucrose gradients (2.0-0.25 M sucrose), or acombination of ultrafiltration (500 K membrane) and ultracentrifugationinto a 30% sucrose/deuterium oxide (98%) cushion (density, 1.210 g/cm³)may also be used. Various methods for the isolation of microvesicles canbe found, for example, in U.S. Pat. Nos. 6,899,863, 6,812,023, Taylorand Gercel-Taylor, Gynecol Oncol 110, 2008: 13-21, Cheruvanky et al., AmJ Physiol Renal Physiol 292, 2007: F1657-61, and Nagrath et al., Nature450, 2007: 1235-9.

Isolation of Microvesicles Via Affinity Capture

In preferred embodiments, isolation of microvesicles is accomplishedusing affinity capture methods. Preferably, these affinity methods areimmunoaffinity methods, but in certain embodiments, such methods employother reagents which bind specifically to H2AX. Such methods can be astep in other methods prior to detection of H2AX described above.

As a first step, the entire population of microvesicles may be isolatedby contacting biological samples containing microvesicles with a reagentspecific to a protein commonly found on the surface of all microvesiclesregardless of origin (i.e., microvesicle-specific reagents). In certainembodiments, the reagents are specific to the following proteins:membrane adhesion proteins (integrins), membrane transport/traffickingproteins (annexins and Rab proteins, such as Rab guanosinetriphosphatase), cytoskeletal components (actin, tubulin, ERM proteins,lysosomal markers, and tetraspanin proteins, such as CD9, CD63, CD81,and CD82), antigen presenting proteins (HLA class I and II), deathreceptors, cytokines and cognate receptors (TNF, TNFR1, and TGF-β), irontransport proteins, enzymes (enolase), cytosolic proteins (Hsc73 andHsc90), subunits of trimeric G proteins, Tsg101, milk-fat globule(MFG)-E8, lactadherin, MHC class I molecules, heat shock proteins (Hsp70and Hsp90), drug transporter proteins, or signal transduction proteins.In certain embodiments, reagents are specific to microvesicles fromspecific cell types such as class II MHC and co-stimulatory molecules(CD86) from antigen-presenting cells, von Willebrand factor or CD41a(GPIIb) from platelets, TCR from T-cells, or perforin or granzyme fromcytotoxic T cells (Caby el al., Inter Immunol 17(7); 879-887; 2005).Reagents specific for lipids on the surface of microvesicles may also beused. For example, in preferred embodiments, the immunoaffinity captureincludes use of an anti-phosphatidylserine antibody which binds tomicrovesicles having phosphatidylserine molecules with the polar side ofthe molecule exposed on its outer surface. The antibody is preferablymonoclonal, but can also be polyclonal. In other embodiments, the firststep isolates a specific sub-population of microvesicles, for example,those derived from endosomes or those derived from plasma membrane usingantibodies specific to these sub-populations.

Alternatively, as a first step, microvesicles may first be contactedwith a reagent which binds specifically to microvesicles which arederived from a cancerous cell (i.e., cancer-derivedmicrovesicle-specific reagent). Such a reagent may be one that bindsonly to microvesicles derived from cancerous cells or one that binds toany composition, such as a microvesicle, which displays certaincancer-specific proteins on its surface. If the reagent is the latter,the methods described herein will also include a step for isolatingmicrovesicles or distinguishing them from other compositions found inthe samples. Exemplary cancer-derived microvesicle-specific reagentsinclude antibodies specific to tumor cell surface proteins or tumorantigen proteins. In certain embodiments, these proteins include tumorsurface antigens, tumor invasion-related proteins, angiogenesisproteins, immune-suppressing cytokines, integrin proteins, andproteases. In certain embodiments, these proteins includecancer-specific cell-surface proteins such as those listed below inTable 1. Several studies have identified proteins specific tomicrovesicles derived from various tumor types (see, for example, Bard,M P et al., Am J Respir Cell Mol Biol. 2004 31(1):114-21; Hegmans, J Pet al., Am J Pathol. 2004; 164(5):1807-15; Mears, R et al., Proteomics.2004; 4(12):4019-31; and Choi, D S et al., J Proteome Res. 2007;6(12):4646-55). These antibodies are preferably monoclonal, but can alsobe polyclonal. In preferred embodiments, the cancer-derivedmicrovesicle-specific reagent is a reagent specific forphosphatidylserine, EGFRvIII, IDH1, PDGFRalpha, VEGFR, or α_(v)/β_(III)integrin.

TABLE 1 Cancer-Specific Markers Cancer-Specific Markers APC C18orf8C6orf138 CD44 CDH1 CDH11 CDH6 CDKN2A CDON CEP76 CTNNA1 CTNNB1 DHH FATFGF9 FIGF FKBP8 FLT1 FLT4 FN1 FXYD5 GLI1 GLI2 GLI3 GSK3B HHAT HHIP IFT52IHH ITGA7 ITGB3 KDR KITLG LAMR1 MCAM MGAT5 MMP10 MMP11 MMP13 MMP2 MMP3MMP7 MMP9 MTSS1 NF1 NF2 NPC1 NPC1L1 NRP1 NRP2 OTX2 PDGFC PGF PNN PTCH1PTCH2 PTCHD1 PTCHD2 PTCHD3 RPSA SHH SIAH1 SMO SUFU SYK TGFB1 TIMP2 TIMP3TIMP4 VEGF VEGFA VEGFB VEGFC

In other embodiments, the cancer-derived microvesicle-specific reagentonly binds to cancer-derived microvesicles derived from certain tissuetypes. In this case, the cancer-derived microvesicle-specific reagent isalso a tissue-specific reagent.

Before, subsequent to, or at the same time as capture with a firstmicrovesicle-specific or cancer-derived microvesicle-specific reagent,the microvesicles, either in isolated form or found in the biologicalsample, can be contacted with a tissue-specific reagent to isolatemicrovesicles derived from a specific tissue. Exemplary tissues ofinterest include brain, adrenal gland, endocrine gland, pituitary,hypothalamus, parathyroid, uterus, heart, blood vessel, stomach,trachea, pharynx, gums, hair, scalp, subcutaneous tissue, Fallopiantube, reproductive tract, urethra, skin, bone, stem cell, umbilicalcord, placenta, lymphocyte, monocyte, macrophage, formed blood cell,smooth muscle, skeletal muscle, connective tissue, spinal cord, kidney,bladder, anus, bone, breast, prostate, lung, cervix, colon, rectum,uterus, esophagus, skin, liver, pharynx, mouth, neck, ovary, pancreas,lung, eye, intestine, mouth, thyroid, GI tract, and endometrium.

In certain embodiments, there is a third step of contacting themicrovesicles with an organelle-specific reagent and isolating themicrovesicles derived from organelles of cells in a specific tissue.Particular organelles of interest include plasma membrane, peroxisome,smooth ER, rough ER, lysosome, mitochondria, and nucleus.

In some embodiments, each step is performed using multiplemicrovesicle-specific, cancer-derived microvesicle-specific, ortissue-specific reagents.

In preferred embodiments, an anti-tenascin-C specific antibody is usedto isolate microvesicles from brain tissue. In other preferredembodiments, microvesicles derived from certain tissues are isolatedusing antibodies to tissue markers known to those of skill in the art.For example, markers for brain tissue include VLP-1,synaptosomal-associated protein, GAD67, myelin-associatedoligodendrocyte basic protein, synaptotagmin I, tubulin β 4, zygin,glycine receptor β, protein 1 kinase C and casein kinase substrate inneurons 1, internexin neuronal intermediate filament protein a,neuroserpin, synaptobrevin 2, or neurogranin (Laterza et al.; Clin Chem52:9; 1713-21; 2006).

In related embodiments, subsequent to capture with a firstmicrovesicle-specific/cancer-derived microvesicle-specific reagent, theentire population of microvesicles is contacted with an reagent whichbinds to microvesicles derived from multiple tissue types rather thanone that binds microvesicles derived from a specific tissue.

In preferred methods for isolating microvesicles derived from specifictissue(s), the method includes contacting a biological sample with anreagent specific for microvesicles, preferably a reagent specific forphosphatidylserine, wherein the biological sample includes microvesiclesand the reagent binds to microvesicles; contacting the microvesicleswith a tissue-specific reagent and then isolating the microvesiclesderived from the tissue(s).

In particularly preferred embodiments, methods for isolatingmicrovesicles derived from brain cancer tissue from blood include thesteps of providing blood; providing plasma by centrifuging the blood;contacting plasma with an anti-phosphatidylserine antibody in aphysiological buffer, wherein the anti-phosphatidylserine antibody bindsto microvesicles; isolating microvesicles bound by theanti-phosphatidylserine antibody; contacting the microvesicles with ananti-tenascin antibody; and isolating the microvesicles derived frombrain cancer tissue. Preferably, the plasma is contacted with ananti-phosphatidylserine antibody for about 60 minutes and themicrovesicles are isolated by changing the ionic strength of thephysiological buffer.

Affinity Steps

Contacting a biological sample with an microvesicle-specific reagent orcancer-derived microvesicle-specific reagent and contacting themicrovesicles with a tissue-specific reagent may occur in a single step.Under such circumstances, the reagents may be coupled to the same solidsupport. Alternatively, the steps are performed sequentially. Thebiological sample is first contacted with a microvesicle-specificreagent/cancer-derived microvesicle-specific reagent and then contactedwith a tissue-specific reagent, sometimes with an intervening step ofisolating the microvesicles bound by amicrovesicle-specific/cancer-derived microvesicle-specific reagent. Thesteps may also be reversed, such that biological sample is firstcontacted with a tissue-specific reagent and then amicrovesicle-specific/cancer-derived microvesicle-specific reagent,sometimes with an intervening step of isolating a fraction bound by thetissue-specific reagent.

Contacting the biological sample and the reagents occurs for a suitableincubation time which optimizes the efficiency of themicrovesicle/tissue marker:reagent interaction. It is well within thecompetence of one of ordinary skill in the art to determine theparticular conditions based on the disclosure herein. Typically, thebiological sample and reagents are incubated together in a suitablebuffer at physiological pH at a suitable temperature (e.g., about 4-37°C.), for a suitable time period (e.g., about 60 minutes to overnight) toallow the binding to occur.

Once bound by reagent, microvesicles are isolated using standard methodsknown to those of skill in the art. For example, if the microvesiclesare bound to an immunoaffinity resin, the resin is washed withphysiological buffers, such as Tris-Acetate pH 7.6 to remove otherunbound components of the biological sample and then eluted by changingthe ionic strength of the buffer for the resin, for example, bygradually increasing the concentration of a salt, such as NaCl, CaCl₂,KCl, MgCl₂, or similar salts that cause the reagent to release the boundmicrovesicles. Sepharose 2B columns may also be used for size exclusionmethodologies of isolating microvesicles (Taylor et al., 2012).

Solid Support and Column Configuration

The reagents are typically coupled to solid supports. A solid support,for purposes of the present disclosure, can be any material that is aninsoluble matrix and can have a rigid or semi-rigid surface to anreagent can be linked or attached. Exemplary solid supports include, butare not limited to, substrates such as nitrocellulose,polyvinylchloride; polypropylene, polystyrene, latex, polycarbonate,nylon, dextran, chitin, sand, silica, pumice, agarose, cellulose, glass,metal, polyacrylamide, silicon, rubber, polysaccharides, polyvinylfluoride, diazotized paper, activated beads, magnetically responsivebeads, and any materials commonly used for solid phase synthesis,affinity separations, purifications, hybridization reactions,immunoassays and other such applications. The support can be particulateor can be in the form of a continuous surface and includes membranes,mesh, plates, pellets, slides, disks, capillaries, hollow fibers,needles, pins, chips, solid fibers, gels (e.g. silica gels) and beads,(e.g., pore-glass beads, silica gels, polystyrene beads optionallycross-linked with divinylbenzene, grafted co-poly beads, polyacrylamidebeads, latex beads, dimethylacrylamide beads optionally crosslinked withN-N′-bis-acryloylethylenediamine, iron oxide magnetic beads, and glassparticles coated with a hydrophobic polymer.

Typically, the solid support is a bead or resin in a columnconfiguration. In preferred immunoaffinity capture methods for isolatingmicrovesicles of interest, the method includes providing a column,applying a biological sample suspected of containing one or more of themicrovesicles of interest to bind to resins in the column, washing thecolumn, eluting the resins and analyzing the eluant for the presence ofthe microvesicles of interest. More specifically, such methods caninclude loading the column with a predetermined amount of a biologicalsample suspected of containing the microvesicles of interest in eitherblood plasma or a physiological buffer; binding the microvesicles to thereagent on the column; loading the column with a wash solution,suspending the resin in the wash solution; removing the wash solutionfrom the column; eluting the microvesicles in eluant; and analyzing theeluant for the presence of the microvesicles.

In certain embodiments, it is preferred that that the columnconfiguration used in such methods allows for suspension of the resinbeads, such as a mobile bead column or other resin during washing. Ithas been discovered that such a column configuration results insignificantly lower levels of background and hence more sensitive levelsof quantitation and overall yield of the desired target.

In certain embodiments, the column used in such methods includes a lowerend including an outflow opening; a lower porous support; a layer ofresin on the lower porous support, the resin having specific affinityfor all microvesicles or tissue-specific microvesicles; an upper poroussupport; and an upper end including an inflow opening; wherein the resinbetween the lower porous support and the upper porous support isstructured and arranged to permit removal of the upper porous supportfrom the column without substantial removal of resin.

In other embodiments, the resin is fixed between two semi-porous fritssuch that the resin beads may be suspended and such that the upper fritmay be removed during washing of the resin to remove backgroundcompounds.

The volume of the resin in the column can vary but is typically lessthan the total packed volume of the column between the lower poroussupport and the upper porous support. Preferably, the volume of theresin in the column is no greater than 50%, more preferably no greaterthan 40%, even more preferably no greater than 30%, still morepreferably no greater than 25%, and still more preferably no greaterthan 20% of the total packed volume of the column between the lowerporous support and the upper porous support.

Analysis of H2AX Expression Levels

Described herein are methods of monitoring genotoxic stress due tocancer treatment in a test subject, specifically by detecting theexpression level of microvesicle-associated H2AX.

In certain embodiments, methods include comparing the expression levelof H2AX in the biological sample from the test subject with theexpression level of H2AX in a biological sample from a control subjectthat is not given the cancer treatment. The expression levels frombiological samples from the plurality of control subjects may besimultaneously obtained with the test subject expression levels or mayconstitute a set of numerical values stored on a computer or on computerreadable medium. In preferred embodiments, the control subjects are ofthe same sex and of a similar age as the test subject. Control subjectsmay also be of a similar racial background as the test subject.Preferably, biological samples taken from the test subject and from theplurality of control subjects are of the same type, e.g., blood samples.

Comparison of the expression levels of the one or moremicrovesicle-associated H2AX in biological samples from the test subjectand from a plurality of control subjects may be performed manually orautomatically by a computer program. The expression level of H2AX in thebiological sample from the test subject may be compared individually tothe expression level of the microvesicle-associated H2AX from biologicalsamples in each control subject, or the expression level ofmicrovesicle-associated H2AX in the biological sample from the testsubject may be compared to an average of the expression levels frombiological samples from the plurality of control subjects. In certainembodiments, the values for the expression levels of H2AX in biologicalsamples from both the test subject and the plurality of control subjectsmay be transformed. For example, the expression levels may betransformed by taking the logarithm of the value. Moreover, theexpression levels may be normalized by, for example, dividing by themedian expression level among all of the samples.

In certain embodiments, the expression level of microvesicle-associatedH2AX in the biological sample from the test subject is increasedrelative to the expression level of the one or moremicrovesicle-associated H2AX in biological samples from a plurality ofcontrol subjects. In other embodiments, the expression level ofmicrovesicle-associated H2AX in the biological sample from the testsubject is decreased relative to the expression level ofmicrovesicle-associated H2AX in biological samples from a plurality ofcontrol subjects.

Practicing the Methods

The steps of the method may be practiced by either one or more than oneentity. An entity may be, for example, a person, a group of people, aninstitution, or a business.

One Entity

According to certain aspects, the steps required to practice the methodare practiced by one entity. In certain embodiments, a single entity maydetect the expression levels of microvesicle-associated H2AX in abiological sample from the test subject and then monitor the cancertreatment or determine the efficacy of cancer treatment. This entity maybe, for example, a doctor or a clinician. This entity may also be aninstitution, such as a hospital or a doctor's office, where all steps ofthe methods are performed by employees of the institution.

In other embodiments, a single entity may detect the expression levelsof microvesicle-associated H2AX in a biological sample from the testsubject and communicate the expression levels to a different entity thatthen monitors the cancer treatment or determines the efficacy of thecancer treatment. In these embodiments, the single entity performing thesteps of detecting and communicating may be, for example, a clinic or alab technician.

More than One Entity

According to other aspects, the steps required to practice the methodmay be performed by more than one entity. One entity may detect theexpression levels of microvesicle-associated H2AX in a biological samplefrom the test subject, whereas a different entity may monitor the cancertreatment or determine the efficacy of the cancer treatment. Forexample, a lab technician at a clinic may detect the expression levelsof H2AX in a biological sample from the test subject, and a doctor at ahospital may determine the efficacy of the cancer treatment.

Communication between Entities

Communication between entities in practicing methods may occur by anymeans used in the art. Typically, information communicated betweenentities will be in the form of a report. In certain embodiments, afirst entity may obtain expression levels of microvesicle-associatedH2AX in a biological sample from the test subject from a second entitythat detects the expression levels of microvesicle-associated H2AX in abiological sample from the test subject. The first entity may obtain theexpression levels from the second entity directly or indirectly. Forexample, the first entity may obtain a paper or electronic report of theexpression levels directly from the second or different entity. Inanother example, the first entity may obtain an electronic report of theexpression levels on a network to which the second entity has uploadedthe report. In yet another example, the first entity may obtain theexpression levels from a third entity that has prepared a report fromthe detections by the second entity.

In other embodiments, a first entity may detect the expression levels ofmicrovesicle-associated H2AX in a biological sample from the testsubject and communicate the expression levels to a second or differententity that then monitors the cancer treatment or determines theefficacy of the cancer treatment. The first entity may communicate theexpression levels to the second entity directly or indirectly. Forexample, the first entity may prepare a report with the expressionlevels and give the report to the second entity manually orelectronically. In another example, the first entity may upload theexpression levels to a network from which the second entity can obtainthe levels. In yet another example, the first entity may communicate theexpression levels to a third entity that prepares a report for use bythe second entity.

Clinical Trials

Methods described herein may be useful for clinical trials involvingcancer. Typically, for their use in clinical trials, the steps requiredto achieve the objects of the invention will be practiced by more thanone entity. For example, multiple entities in different locations, suchas clinics in different cities, may detect the expression levels of theone or more microvesicle-associated proteins in a biological sample fromthe test subject and communicate the expression levels to a differententity, such as a group of doctors directing the clinical trial, whothen determine the efficacy of the cancer treatment. In certainembodiments, the multiple entities may use a third entity that preparesand communicates reports of the expression levels to the differententity that determines the efficacy of the cancer treatment. Clinicaltrials involving the described methods may be useful for evaluatingeffectiveness of new drugs and treatments for cancer or for evaluatingthe effects of various clinical parameters on cancer and itsprogression.

Reagents and Kits

Also provided are reagents and kits thereof for practicing one or moreof the above-described methods. The subject reagents and kits thereofmay vary greatly. Reagents of interest include reagents specificallydesigned for use in detection of the above-described expression levelsof microvesicle-associated H2AX.

One type of such reagent is an array or kit of antibodies that bind to abiomarker cluster of interest. A variety of different array formats areknown in the art, with a wide variety of different probe structures,substrate compositions, and attachment technologies. Representativearray or kit compositions of interest include or consist of reagents forquantitation of at least 1 microvesicle-associated protein, such asH2AX.

The kits may further include a software package for statistical analysisof one or more phenotypes, and may include a reference database forcalculating the probability of classification. The kit may includereagents employed in the various methods, such as devices forwithdrawing and handling blood samples, second stage antibodies, ELISAreagents, tubes, spin columns, and the like.

In addition to the above components, the subject kits will furtherinclude instructions for practicing the subject methods. Theseinstructions may be present in the subject kits in a variety of forms,one or more of which may be present in the kit. One form in which theseinstructions may be present is as printed information on a suitablemedium or substrate, e.g., a piece or pieces of paper on which theinformation is printed, in the packaging of the kit, in a packageinsert, etc. Yet another means would be a computer-readable medium,e.g., diskette, CD, etc., on which the information has been recorded.Yet another means that may be present is a website address which may beused via the internet to access the information at a removed site. Anyconvenient means may be present in the kits.

EXAMPLES

The following examples are offered for illustrative purposes and to aidone of skill in better understanding the various embodiments of thedisclosure. The following examples are not intended to limit the scopeof the present disclosure in any way.

Example 1-Unphosphorylated H2AX and γH2AX as Markers of Genotoxic Stress

The following example demonstrates that microvesicle-derivedunphosphorylated H2AX and microvesicle-derived γH2AX are markers ofgenotoxic stress in a cell. Treatment of U87 brain cancer cells with theDNA alkylating agent temozolomide (TMZ) induced increased abundance ofH2AX and γH2AX proteins in microvesicles derived from the U87 cells.

Materials and Methods Overview of Microvesicles Harvested from TumorCell Lines-Experimental Outline

U87 MG (ATCC® HTB14™) cell cultures represent glioblastoma multiforme(GBM). An Integra CELLine Bioreactors (Hudson, N.H.) was seeded fromT-75 cultures of U87 into the 15 ml lower chamber, separated by a 10 kDaMWCO filter from a 500 ml upper reservoir chamber. After growth wasestablished in the lower chamber containing exosome free fetal bovineserum (Exo-FBS Systems Biosciences, Mountain View Calif.), supernatantsamples were recovered on a weekly basis. Upper chambers of thebioreactors were replenished with normal fetal serum-containing medium.The cultures used were between 4 and 5 months old and were monitored forcontinued robust health.

On day 1 of the study, the Integra bioreactor was provided with normalEagles minimal essential medium (EMEM) supplemented with exosome-freefetal bovine serum FBS. Additionally fresh media was added to the upperchamber. Supernatant samples were taken at 2, 4, 6, and 24 hours afteraddition of fresh medium, mixed with protease inhibitor and Vencereminpeptide reagent (New England Peptide, Gardner, Mass.) for incubation at4° C.

Culture supernatants were collected at 24 hours. Fresh medium was addedto both the lower and upper chamber adjusted to 100 μm TMZ was added(day 2) and supernatant samples taken as indicated above. The processwas repeated at 48 hours with the exception that fresh media had beenadjusted to 300 μm TMZ (day 3). The final collection of lower chambersupernatant occurred at 72 h.

Microvesicles in the conditioned media were recovered from culturesupernatants using one of the Venceremin peptides (New England Peptide,Gardner Mass.). Venceremins were originally identified as ligands withstrong avidity for heat shock proteins, particularly HSP90 and ofvariable affinity to isoforms of HSP70, HSP60 and other chaperoneproteins. Microvesicles from pathologically affected cells, particularlycancer, display HSPs on the external surface. To recover microvesicles,the Venceremin peptide Vn96reverse, referred to as Heladonin (Hdn:H2N-LKLFEGLTLAGWSFRSLSLGRGKGQSP-OH), was used. The Integra bioreactorlower chamber supernatant samples (2 mls) were mixed with 101 ofprotease inhibitor and 50 μg of Hdn peptide stock solution.Microvesicles were prepared from Bioreactor supernatant samples taken at2, 4, 6 and 24 hours after addition of fresh medium and placed at 4° C.

All samples were incubated for at least 18 h. The samples were processedby centrifugation (4500 g) washing in 1 ml of PBS and repeatcentrifugation. The presence of U87 microvesicles in material pelletedfrom the lower chamber of the cell cultures was determined by Westernblotting.

Cell Culture Media

Exosome-free fetal bovine serum (FBS) supplement was purchased fromExo-FBS Systems Biosciences, Mountain View Calif. Eagles minimalessential medium (EMEM) supplied by ATCC Cat #30-2003. Complete 10%fetal bovine serum 90% EMEM was placed in the upper reservoir chamber ofthe CELLine Bioreactor. Prior to introduction of U87 cells into thebioreactor, the bioreactor was provided with Eagle's minimum essentialmedium+100 U/ml penicillin+100 μg/ml streptomycin (EMEM)+10%exosome-free fetal bovine serum FBS. After U87 cell introduction intothe bioreactor, the bioreactor was cultured at 37° C. in a 5% carbondioxide atmosphere. Upper chamber contains EMEM supplemented regularfetal bovine serum. A control bioreactor containing 15 mls ofEMEM+Exo-free Medium placed at 37° C. was used. 2mls were taken from thecontrols each day and replaced with fresh medium.

Temozolomide (TMZ) Preparation

The MW of TMZ is 194.151 g/mol. 100 mg TMZ was dissolved in 5 ml of DMSO(20 mg/ml TMZ), which is equivalent to 20 μg/μl TMZ (257 mM). The stocksolution of TMZ was used to provide TMZ at designated concentrations inthe culture media of the bioreactor.

Day 1 Protocol-Introduction of Fresh Serum-EMEM to Bioreactor Culture(No TMZ)

The culture received fresh SBI Exosome-free serum supplemented media inlower chamber and regular FBS-supplemented media in the upper chamberand placed in a 37° C. incubator. At 2, 4 and 6 h the bioreactor wasretrieved from the incubator and rocked gently for 1 min. 2 mls of mediawere removed from the lower cell chamber and transferred to 2.0 mlHANDEE microcentrifuge tube (PIERCE Rockland II) containing 5 ul ofprotease inhibitor (Cocktail III, EMD Merck Millipore). 2 mls of freshmedia was added to upper chamber to compensate for removal. Theretrieved volumes of supernatant (SN) were centrifuged at 17000 g for 5m at 4° C. to pellet microparticulates and cell debris. 1.8 mlsupernatant was transferred to a new tube taking care to avoid anypelleted material. The SN was mixed with 10 μl of Hdn peptide stocksolution and incubated at 4° C. overnight for microvesicle recovery. Thecell and microparticle pellet (17000 g) was stored at −80° C.

Day 2 Protocol-Recovery of Microvesicle Population and Introduction ofNew Media Containing 100 μM TMZ

After 24 h the bioreactor flask was retrieved from incubators and rockedgently for 5 m. All of the culture medium was retrieved from the lowercell chamber and immediately replaced with fresh EMEM with Exo-FBScontaining 100 μM TMZ stock solution. 100 μM TMZ was also added to theupper chamber.

For the 24 hour microvesicle sample, 2 ml samples of SN were transferredto HANDEE tubes containing 5 μl of protease inhibitor as for the 2, 4and 6 h samples and placed at 4° C. All remaining culture SN was frozenat −80° C. The cell free solutions serving as negative controls werealso processed in an identical manner.

Day 3 Protocol-Recovery of Microvesicle Population and Introduction ofNew Media Containing 300 μM TMZ

Replacement of media and processing of samples for the collection ofmicrovesicles was conducted in the same manner as day 2 with theexception that serum-supplemented EMEM was adjusted to 300 μM TMZ inboth upper and lower chambers of the CELLine Bioreactor.

Day 4 Protocol-Final Collection of Culture Supernatant

Replacement of media and processing of samples for the collection ofmicrovesicles was conducted in the same manner as day 2 with theexception that no further addition of TMZ was given to the cultures andthe collection of lower chamber supernatant was considered the end ofthe experiment. The accumulated microvesicle samples were stored at 4°C. for a minimum of 18 h for processing together on day 5 in preparationfor gel electrophoresis.

Preparation of Microvesicles

All SN samples stored at 4° C. with Hdn peptide and protease inhibitorwere centrifuged at 4500 g for 5 m at 4° C. The SNs were utilized toisolate the microvesicle pellets. Protein pellets were resuspended in 1ml of PBS by vortexing and returned to the microcentrifuge for 5 m at4500 g at 4° C. Protein pellets were prepared for electrophoresis byresuspension in a variant of Laemmli SDS buffer as previously described(Wubbolts et al., 2003). The premixed 4×XT loading buffer (Bio-Rad) wasadjusted to 4M urea, 25 mM TCEP (reducing agent; PIERCE) and 5 μl/ml ofprotease inhibitor (Cocktail III EMD Milipore). The electrophoresissample/loading buffer was referred to as “USB” for urea sample buffer.Samples were incubated at 95° C. in a dry-heating block for 5 minutes,vortexed vigorously and given a 30 s spin in a microcentrifuge to bringdown droplets and condensation.

Electrophoresis and Blotting Conditions

Frozen samples in SDS/Urea electrophoresis buffer were incubated at 95°C. for 30 seconds, vortexed and microfuged briefly. 25 μl volumes wereapplied to 10% XT Bis-Tris Criterion precast midi gels in XT-MES runningbuffer (all products Bio-Rad Hercules Calif.). Gels were run inCriterion modules (Bio-Rad) for approximately 55 minutes at 150 V. Afterelectrophoresis was complete, the gels were rinsed in Towbin transferbuffer and layered onto supported nitrocellulose, blotting pads andpaper (BioRad), all assembled into a blotting cartridge for insertion inthe Criterion blotting module. The blotting module contained pre-chilledTowbin transfer buffer and an ice pack. Blotting was considered completeby running at 90V for 30 m. The blot was rinsed in distilled deionisedwater and processed with the Pierce reversible protein stain kit. Theimages were captured using a Bio-Rad Chemi-Doc using white light modeand allowed to dry.

Antibody Reactivity and Image Generation

The blots were destained to clear background by rehydration in ddH2O anduse of destaining reagent (PIERCE). The blots were blocked for 30minutes in 5% low-fat skim milk powder dissolved in phosphate bufferedsaline adjusted to 0.075% Tween 20 (TPBS).

The blots were cut longitudinally at the 37 kDa marker (i.e.perpendicular to the direction of electrophoresis) to allow for the samesamples to be probed for low molecular weight (bottom) and highmolecular weight proteins (top). In this instance the target was gammaγH2AX (˜17 kDa Anti-phospho-Histone H2A.X_Ser139: Millipore MABE205).After reactivity to these antibodies had been recorded, the same blotswere incubated with a secondary sequence of H2AX (i.e. unphosphorylatedH2AX anti-Histone H2A.X: Millipore 07-627).

Primary antibody was mixed with 3% milk dissolved in TPBS at a 1:2000dilution and the blot incubated for 60 minutes, washed 4 times with anequal volume of TPBS, incubated by a 1:2000 dilution of horse-radishperoxidase (HRP) secondary antibody, washed 4 times for 10 minutes withTPBS. All incubations rocking and washes were conducted automaticallywith a Freedom Rocker device (Next Advance, Averil Park N.Y.). Theantibody-probed and TPBS washed blot halves were covered with 1 ml ofSuper Signal West Dura HRP substrate (PIERCE), covered with cling filmand imaged using the Chemi-Doc at exposures between 2 s and 60 sdepending on the signal intensity.

Growth Conditions for U87 Cultures Used in Subcellular Protein Analysis

U87 cell cultures were grown as a monolayer in T-75 flasks (Corning, 75cm², ultra low attachment surface). Flask 1 was designated as a controlflask, while Flasks 2 and 3 were treated with 50 μM and 100 μM TMZ,respectively. U87 s were grown in Eagle's Minimum Essential Medium,fetal bovine serum to a final concentration of 10%. Cells were grown to80% prior to dosage with TMZ.

Subcellular Fractionation and Compartment Isolation

Control and TMZ-treated U87 cells were processed into subcellularfractions using the sub-cellular proteome extraction kit (S-PEK, EMDMilipore) according to manufacturer instructions using differentialdetergent extraction with four extraction buffers to isolate proteinsenriched in various cellular compartments. Various buffers were used inthe extraction process to enrich for proteins in specified compartmentsas follows: from the cytoplasmic compartment in Extraction buffer 1(EB1); enriched in membrane-associated proteins, Extraction buffer 2(EB2); enriched in nucleus-associated proteins, Extraction buffer 3(EB3) or enriched in cytoskeletal proteins, Extraction buffer 4 (EB4).All blots on cellular compartment-extracted proteins were conducted asdescribed for microvesicle-isolated proteins.

Results

H2AX and γH2AX are Markers of Genotoxic Stress

Table 2 illustrates the microvesicle samples analyzed in the blotanalyses and the corresponding lanes for the respective samples, theresults of which are depicted in FIG. 1 and FIG. 2A, 2B.

TABLE 2 Identification of Microvesicle Samples in the Specified BlotLanes U87 Media and MCVS Harvested from Lane # Exosome Free CultureMedia 1 5X dilution of MW standard 2 Controls + (SBI) 2 hours 3Controls + (SBI) 4 hours 4 Controls + (SBI) 6 hours 5 Controls + (SBI)24 hours 6 (SBI + 100 μm TMZ) 2 hours 7 (SBI + 100 μm TMZ) 4 hours 8(SBI + 100 μm TMZ) 6 hours 9 (SBI + 100 μm TMZ) 24 hours 10 (SBI + 300μm TMZ) 2 hours 11 (SBI + 300 μm TMZ) 4 hours 12 (SBI + 300 μm TMZ) 6hours 13 (SBI + 300 μm TMZ) 24 hours 14 Blank 15 Control SBI Media 0 16Control SBI Media 1 17 Control SBI Media 2 18 Blank

All samples appeared closely matched in overall intensity of totalprotein profile, with subtle variation in protein intensity at higher(e.g. ˜250 kDa) and lower (10-25 kDa) molecular weight (FIG. 1 , lanes2-13). Protein was also recovered from the exosome-free serum product inthe absence of cell material (FIG. 1 , lanes 15-17; SBI-EFM).

For γH2AX (FIG. 2A), a band migrating between the 15 and 20 kDa markerwas clearly observed at 2, 6 and 24 h after medium replacement, withonly a thin band seen at 4 h (FIG. 2A, lanes 2, 4, 5 and 3). However,γH2AX was uniformly intense in 2, 4, 6 and 24 h microvesicles on day 3following addition of 300 uM temozolomide (TMZ) to the culture media.This study therefore presents the first recorded observation of γH2AX, anuclear biomarker reflecting alkylation of DNA, captured in shedmicrovesicle material. Without wishing to be bound by theory, it isbelieved that the identification of γH2AX on the first day, in theabsence of the DNA damaging agent (TMZ), supports the observation thatthe U87 phenotype is associated with genomic instability due to theobserved release of γH2AX in microvesicles. After 3 days of exposure toTMZ, γH2AX became consistent in intensity and was more abundantfollowing addition of TMZ to the culture media. This latter observationindicates that prolonged exposure to TMZ increases the probability thatγH2AX will be incorporated into microvesicles. γH2AX in microvesiclesmay thus be used as an indicator of phenotypic genomic instability andincreased DNA damage due to drug or radiation exposure.

For H2AX (FIG. 2B), the antibody to unphosphorylated H2AX was usedsecondarily to the same blot probed for γH2AX. It was observed that theprotein expression of H2AX, even in the presence of TMZ, was similar tothat observed for γH2AX. H2AX in microvesicles may thus be used as anindicator of phenotypic genomic instability and increased DNA damage dueto drug or radiation exposure.

H2AX and γH2AX are Nuclear Proteins

Table 3 illustrates the subcellular compartment samples analyzed in theblot analyses and the corresponding lanes for the respective samples,the results of which are depicted in FIG. 3 .

TABLE 3 Identification of Subcellular Compartment Samples in theSpecified Blot Lanes Lane # T-75 Monolayer Flasks 1 5X dilution of MWstandard 2 Blank 3 0 μM TMZ, EB1 4 0 μM TMZ, EB2 5 0 μM TMZ, EB3 6 0 μMTMZ, EB4 7 Blank 8 50 μM TMZ, EB1 9 50 μM TMZ, EB2 10 50 μM TMZ, EB3 1150 μM TMZ, EB4 12 Blank 13 100 μM TMZ, EB1 14 100 μM TMZ, EB2 15 100 μMTMZ, EB3 16 100 μM TMZ, EB4 17 5X dilution of MW standard 18 U87 control

As can be seen in FIG. 3A, γH2AX protein could only be detected innuclear fractions of U87 protein extracts from whole cells, asrepresented by the single detected band marked with an arrow. γH2AXprotein also began to accumulate only in the nucleus followingapplication of TMZ to the cell culture. Similarly, and as can be seen inFIG. 3B, H2AX protein could only be detected in nuclear fractions of U87protein extracts from whole cells (large arrow). A smaller protein wasalso detected in nuclear extracts (small arrow) with an H2AX antibody,possibly representing a degradation product or fragment of H2AX.

In summary, both γH2AX and H2AX proteins could only be detected innuclear fractions of U87 cells, as these proteins were absent fromprotein extracts enriched for cytoplasmic, membrane-associated, andcytoskeletal proteins. These data confirm that both γH2AX and H2AX arenuclear-localized proteins and confirm that the source of the exosomalsignal for γH2AX appears not to be derived from cytoplasmic or membranebound protein.

Example 2—Unphosphorylated H2AX and γH2AX as Tumor Markers

The following example demonstrates that microvesicle-derivedunphosphorylated H2AX and microvesicle-derived γH2AX, which are bothhistone proteins, are relevant tumor markers. These protein markers werefound to be associated with microvesicles shed from various tumor ortumor-like cell lines, including a cervical cancer model cell line(HELA), a glioma model cell line (U87), and a model highly proliferativerenal cell line (HEK293T).

Materials and Methods

Overview of Microvesicles Harvested from Tumor Cell Lines-ExperimentalOutline

HELA (ATCC® ccl-2™), U87 (ATCC® HTB14™), and HEK293T (ATCC® CRL-1573™)cell cultures were grown in Integra CELLine Bioreactors (Hudson, N.H.)after seeding from T-75 cultures into the 15 ml lower chamber, separatedby a 10 kDa MWCO filter from a 500 ml upper reservoir chamber. Aftergrowth was established in the lower chamber containing exosome freefetal bovine serum (Exo-FBS Systems Biosciences, Mountain View Calif.),supernatant samples were recovered on a weekly basis. Upper chambers ofthe bioreactors were replenished with normal fetal serum-containingmedium. The cultures used were between 4 and 5 months old and weremonitored for continued robust health.

Microvesicles in the conditioned media were recovered from culturesupernatants using Venceremin peptides (Vn96, New England Peptide,Gardner Mass.) in conjunction with a variety of wash buffers for thedisaggregation of microvesicles prior to use of Vn96. Microvesicles fromthese cells were harvested in the conditioned media from the Integrabioreactor lower chamber and supernatant samples (2 mls) were mixed with1 Oi of protease inhibitor and 50 μg of Vn96 peptide stock solution.Microvesicles were prepared from Bioreactor supernatant samples taken at2, 4, 6 and 24 hours after addition of fresh medium and placed at 4° C.

Cell Culture Medium

Exosome-free fetal bovine serum (FBS) supplement was purchased fromExo-FBS Systems Biosciences, Mountain View Calif. Eagles minimalessential medium (EMEM) supplied by ATCC Cat #30-2003. Complete 10%fetal bovine serum 90% EMEM was placed in the upper reservoir chamber ofthe CELLine Bioreactor. Prior to introduction of cells into thebioreactor, the bioreactor was provided with Eagle's minimum essentialmedium+100 U/ml penicillin+100 μg/ml streptomycin (EMEM)+10%exosome-free fetal bovine serum FBS. After cells were introduced intothe bioreactor, the bioreactor was cultured at 37° C. in a 5% carbondioxide atmosphere. Upper chamber contains EMEM supplemented regularfetal bovine serum.

Preparation of Microvesicles

Raw Stock Solutions containing U87, HELA, or HEK293T (293T) bioreactorculture medium were concentrated by VivaSpin 1 million Dalton molecularweight cut off (MWCO) spin filters and resuspended in 50 mM amino acidsolution (Stock B) or 5% detergent (Stock D). These solutions wereprepared for electrophoresis directly by adding 50 μl of 3× urea SDSsample buffer (USB) to 100 μl of the stock solutions. After heating at95° C., 15 μl were loaded. Samples of Stock B and Stock D can be seen inlanes 2 and 3 of each blot (FIG. 4 ).

Peptide recovered microvesicles using Vn96 (microvesicle samples) wereprepared by incubating 1.8 ml volumes of CELLiNE Integra bioreactorculture media from U87, HELA, or 293T cells with 50 μg of peptideovernight at 4° C. After incubation of the mixtures were centrifuged at4500 g washed by resuspending in 500 μl of Stock B and re-pelleted bycentrifugation. The supernatant was removed and the pellet resuspendedin 200 μl of 1× urea SDS sample buffer (USB). 15 μl were loaded to thegel. U87, HELA and 293T microvesicle samples are shown in lanes 4-6 ofFIG. 4 . Other samples in FIG. 4 were collected by PD-10 size exclusionchromatography (SEC) using 2% agarose beads and selected buffers.

1 ml sample volumes and 1 ml eluate fractions were collected by gelfiltration procedure PD-10 SEC as discussed herein to form the contentsof peak 1 (fractions 2, 3, 4, and 5). For the analysis, fractions 2 and3 were reduced to minimal volume in a VivaSpin 2 ml 1 million Daltonmolecular weight cut off (MWCO) spin filter; fractions 4 and 5 wereadded on top of the retentate of 2 and 3 and again centrifuged tominimum volume. Samples consisting of fractions 2, 3, 4, and 5,otherwise known as peak 1, were pooled and resuspended in 1 ml of water.The remaining 500 μl was centrifuged to minimum volume and resuspendedin 150 μl of 1× urea SDS sample buffer (USB). 15 μl were loaded to thegel. The concentrated pooled peak 1 fractions were prepared from U87bioreactor culture medium that had been concentrated by VivaSpin 1million Dalton molecular weight cut off (MWCO) spin filters andresuspended in AB Serum (Stock A) as indicated above following the PD-10fractionation into 1 ml volumes fractions 2, 3, and 4.

Mass Spectrometry Protein Analysis

U87 preparations were resuspended into Serum A/B and microvesiclesisolated using gel filtration. Microvesicle particles were isolated andsubjected to protein isolation and tryptic digest. Microvesiclefractions were run on an on 8%, 10%, and 12% T columns using the GELFrEEsystem (Protein Discovery), collecting 12 fractions per column. GELFrEEfractions were processed by acetone precipitation for SDS removalaccording to the method described in Botelho et al. (2010). Fractionswere analyzed via bottom-up LC-MS/MS on a Thermo LTQ mass spectrometerand identified using Scaffold (Proteome Software) and Bioworks, andquantified via spectral counting according to Yates et al. (2004).

Electrophoresis and Blotting Conditions

Frozen samples in SDS/Urea electrophoresis buffer were incubated at 95°C. for 30 seconds, vortexed and microfuged briefly. 25 μl volumes wereapplied to 10% XT Bis-Tris Criterion precast midi gels in XT-MES runningbuffer (all products Bio-Rad Hercules Calif.). Gels were run inCriterion modules (Bio-Rad) for approximately 55 minutes at 150 V. Afterelectrophoresis was complete, the gels were rinsed in Towbin transferbuffer and layered onto supported nitrocellulose, blotting pads andpaper (BioRad), all assembled into a blotting cartridge for insertion inthe Criterion blotting module. The blotting module contained pre-chilledTowbin transfer buffer and an ice pack. Blotting was considered completeby running at 90V for 30 m. The blot was rinsed in distilled deionisedwater and processed with the Pierce reversible protein stain kit. Theimages were captured using a Bio-Rad Chemi-Doc using white light modeand allowed to dry.

Antibody Reactivity and Image Generation

The blots were destained to clear background by rehydration in ddH2O anduse of destaining reagent (PIERCE). The blots were blocked for 30minutes in 5% low-fat skim milk powder dissolved in phosphate bufferedsaline adjusted to 0.075% Tween 20 (TPBS).

The blots were cut longitudinally at the 37 kDa marker (i.e.perpendicular to the direction of electrophoresis) to allow for the samesamples to be probed for low molecular weight (bottom) and highmolecular weight proteins (top). In this instance the target was gammaγH2AX (˜17 kDa Anti-phospho-Histone H2A.X_Ser139: Millipore MABE205).After reactivity to these antibodies had been recorded, the same blotswere incubated with a secondary sequence of H2AX (i.e. unphosphorylatedH2AX anti-Histone H2A.X: Millipore 07-627). In a separate series ofgels, the blots were probed for the presence of pan Histones using theAnti-Histone H4 Antibody: Millipore 04-858.

Primary antibody was mixed with 3% milk dissolved in TPBS at a 1:2000dilution and the blot incubated for 60 minutes, washed 4 times with anequal volume of TPBS, incubated by a 1:2000 dilution of horse-radishperoxidase (HRP) secondary antibody, washed 4 times for 10 minutes withTPBS. All incubations rocking and washes were conducted automaticallywith a Freedom Rocker device (Next Advance, Averil Park N.Y.). Theantibody-probed and TPBS washed blot halves were covered with 1 ml ofSuper Signal West Dura HRP substrate (PIERCE), covered with cling filmand imaged using the Chemi-Doc at exposures between 2 s and 60 sdepending on the signal intensity.

Results

Table 4 illustrates the microvesicle samples analyzed in the blotanalyses and the corresponding lanes for the respective samples, theresults of which are depicted in FIG. 4 .

TABLE 4 Microvesicle Samples in the Specified Blot Lanes Lane #Condition/Source of Protein 1 Molecular weight markers 2 U87 in 50 mMamino acid solution (Stock B) 3 U87 in 5% detergent (Stock D) 4 U87microvesicle sample 5 HELA microvesicle sample 6 HEK293T microvesiclesample

The blots described above were probed to detect specific proteins in thevarious samples (See Table 4 and FIG. 4 ). In all instances with theexception of CD63, the detection of all proteins was strongest in thepeptide recovered microvesicle fractions (microvesicle samples).Antibodies to all histones (pan-histone), H2AX, and γH2AX were stronglyrepresented in the microvesicle samples (lanes 4, 5, and 6), but couldnot be detected in the stock solution lanes (lanes 2 and 3), which wereobtained from cell culture samples and not enriched for microvesicles.Histones are a surface feature of rapidly dividing cells, such ascancers. The data presented in FIG. 4 suggests that histones areincorporated into shed microvesicles from tumor cells. Without wishingto be bound by theory, it is also thought that, as histones may be partof nucleosomes, they may be shed from the cells in membranous form. Therich presence of histones in the tumor cell-derived microvesicle samplescould also be detected by analysis with mass spectrometry, as shown inTable 5 below.

TABLE 5 Identification of Histones in Microvesicle Samples by OMS GeneDescription Peps kDa HIST1H2BK Histone H2B type 1 -K 4 14 HIST2H2ACHistone H2A type 2-C 4 14

Although the total protein load indicates that proteins from themicrovesicle samples are loaded in equal amounts, U87 is identified asbeing the strongest in association with the well-known canonical markerCD63. However although widely regarded as an archetypic marker, CD63 isnot strongly expressed on HELA or 293T.

In summary, the data reveals that histone proteins, such as H2AX andγH2AX, are enriched in tumor-derived microvesicles. This suggests thathistone proteins may be useful as tumor markers.

REFERENCES

-   Wubbolts R, Leckie R S, Veenhuizen P T, Schwarzmann G, M6bius W,    Hoernschemeyer J, Slot J W, Geuze H J, Stoorvogel W. J Biol Chem.    2003 Mar. 28; 278(13):10963-72.-   Taylor, C. G., Atay, S., Tullis, R. H., Kesimer, M and Taylor, D. D.    Anal. Biochem. 2012, 28(1): 44-53.-   Botelho et al. J. Proteome Res. 2010, 9, 2863-2870.-   Yates et al. Anal. Chem. 2004, 76, 4193-4201.

1. A method of monitoring genotoxic stress in a test subject,comprising: detecting the expression level of microvesicle-associatedH2AX in a biological sample from the test subject, and monitoringgenotoxic stress in the subject based on the expression level of themicrovesicle-associated H2AX.
 2. The method of claim 1, wherein thegenotoxic stress is due to environmental contamination with genotoxinsor radiation exposure.
 3. The method of claim 1, wherein the genotoxicstress is due to cancer treatment.
 4. The method of claim 3, wherein thecancer treatment comprises exposure to radiation.
 5. The method of claim3, wherein the cancer treatment comprises administration of ananti-cancer agent selected from the group consisting of a platinumanalogue, a tetrazine, an anti-metabolite, a plant alkaloid orterpenoid, a cytotoxic antibiotic, a DNA alkylating agent, or a type Itopoisomerase inhibitor. 6-10. (canceled)
 11. The method of claim 3,further comprising detecting the expression level ofmicrovesicle-associated H2AX in a biological sample from the testsubject at a plurality of time points following administration of thecancer treatment.
 12. The method of claim 3, wherein monitoring thegenotoxic stress comprises comparing the expression level ofmicrovesicle-associated H2AX in the biological sample from the testsubject with the expression level of H2AX in a biological sample from acontrol subject that is not given the cancer treatment.
 13. The methodof claim 12, wherein a higher level of expression ofmicrovesicle-associated H2AX in the biological sample from the testsubject compared to the level of expression of microvesicle-associatedH2AX in the biological sample from the control subject indicates thatthe cancer treatment is inducing genotoxic stress.
 14. The method ofclaim 3, wherein monitoring genotoxic stress comprises evaluating theefficacy of cancer treatment.
 15. The method of claim 14, whereinevaluating the efficacy of the cancer treatment in the test subjectcomprises comparing the expression level of microvesicle-associated H2AXin the biological sample from the test subject with the expression levelof microvesicle-associated H2AX in biological samples from a pluralityof control subjects. 16-17. (canceled)
 18. The method of claim 15,further comprising a step of deriving a score from the comparison of theexpression level of microvesicle-associated H2AX in the biologicalsample from the test subject with the expression level ofmicrovesicle-associated H2AX in the biological samples from theplurality of control subjects, wherein the score indicates a level ofsimilarity between the expression level of microvesicle-associated H2AXin the biological sample from the test subject and the expression levelof microvesicle-associated H2AX in the biological samples from theplurality of control subjects.
 19. (canceled)
 20. The method of claim18, wherein the score is a correlation coefficient.
 21. The method ofclaim 3, wherein the cancer comprises a solid tumor.
 22. The method ofclaim 3, wherein the cancer is selected from the group consisting ofpancreatic, ovarian, adenocarcinoma, prostate, breast, brain, head,neck, and lymphoma cancers. 23-24. (canceled)
 25. The method of claim 1,wherein the biological sample is selected from the group consisting ofplasma, serum, cerebrospinal fluid, urine, tears, milk, lymph fluid,synovial fluid, bronchoalveolar lavage, amniotic fluid, saliva, ocularfluid, ascites, and respiratory droplets.
 26. The method of claim 1,wherein detecting the expression level of microvesicle-associated H2AXcomprises the use of ELISA, flow cytometry, or liquidchromatography-mass spectrometry.
 27. The method of claim 1, whereindetecting the expression level of microvesicle-associated H2AX comprisesdetecting binding of H2AX to an microvesicle-associated H2AX-specificantibody. 28-29. (canceled)
 30. The method of claim 3, furthercomprising a step of isolating cancer-derived microvesicles from thebiological sample prior to detecting the expression level ofmicrovesicle-associated H2AX.
 31. The method of claim 30, whereinisolating microvesicles from the biological sample prior to detectingthe expression level of microvesicle-associated H2AX comprises:contacting the biological sample with a cancer-derivedmicrovesicle-specific reagent, wherein the biological sample comprisesmicrovesicles and the reagent binds to microvesicles; contacting themicrovesicles with a tissue-specific reagent; and isolating themicrovesicles derived from the tissue.
 32. The method of claim 1,wherein the H2AX is γH2AX.